Ultra Nasdaq Biotechnology 2X ETF (BIB)

N/A +N/A (N/A)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume N/A
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:48 PM
$BFS $BHC $BHR $BIB $BIGY 🔥
0 · Reply
Peachtreegal
Peachtreegal Oct. 17 at 3:35 PM
$ARTV $IBBQ $BIB
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 17 at 3:27 PM
Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally $ARTV $IBBQ $BIB https://stocktwits.com/news/equity/markets/artiva-biotherapeutics-gets-price-target-hike-from-wedbush/ch6sW9tR38A
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 16 at 3:22 PM
$FBIO + ( $DERM ) Older copper injections, sometimes prepared in-house, could be painful and, with long-term use, could cause kidney damage. In clinical trials for CUTX-101, adverse events were generally not considered related to the study treatment, highlighting its improved safety profile. Enhanced bioavailability and safety The specific formulation of CUTX-101 ensures better delivery of copper to the body and brain, where it is critically needed. CUTX-101 has been granted Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations. These designations recognize the drug's potential to provide significant clinical improvement over existing treatments for a rare condition with unmet medical needs. $DERM ( subsidiary of $FBIO OWNS ACCUTANE, see screenshots and link for how it helps treat male infertility . https://www.livescience.com/health/fertility-pregnancy-birth/acne-drug-accutane-may-restore-sperm-production-in-infertile-men-early-study-hints $BIB $JNJ
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 15 at 10:58 PM
$FBIO Updated link, more here: For more info on FIRST EVER TREATMENT for MENKES Disease, a Pediatric, often Fatal Condition, Pending Sept 30th PDUFA for $FBIO. And for latest Isotretinoin and Male Infertility Treatment studies, using Istotretinoin, AKA, ACCUTANE, which is owned by $DERM, a subsidiary of $FBIO, that can treat Male Infertility, based on recent studies. See link below and read quoted post below . https://x.com/ravagelaserbeak/status/1967719314229997659 Related tickers: $DERM $BIB $JNJ $MRK
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 15 at 8:31 PM
$FBIO + $DERM ($DERM is a subsidiary of $FBIO ) Aside from Sept 30th PDUFA = we have this = " For men with infertility caused by extremely low sperm counts or a complete lack of sperm, the only medical option is to undergo surgery to collect sperm directly from the testicles to then use for in vitro fertilization (IVF). But this is a significant surgery that involves discomfort; potential risks, such as infection; and a prolonged recovery period. Moreover, the surgery only yields sperm about half the time. Now, researchers are exploring an alternative: isotretinoin, better known as Accutane, a drug that has been used for decades to treat severe acne. In a small study published in July in the Journal of Assisted Reproduction and Genetics, the drug stimulated sperm production in some men who at baseline had no or very few sperm in their ejaculate. " Good Post on $FBIO More here = https://x.com/ravagelaserbeak/status/1967686200199889335?s=46 related tickers = $BIB $DERM $PFE $JNJ
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 3 at 4:58 PM
$GOOGL OH and we have our own Blockchain now to compete against $XRP lol.... and we're also $BIB on Pharma Treatment discovery by a Nobel Prize Laureate leading Google Deepmind, Demis Hassabis. Long. Price correcting up, now that Browser hurdle has been cleared, likely supports around 350+ in a few weeks. This is re-rate and has ZERO to do with Macro environments. The ONLY thing that had this down is eviscerated and completely gone.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 27 at 3:13 PM
$SSYS Im long $SSYS with Debbie Wasserman Schultz...Debbie Knows...things.... Stratasys posted this about 10 minutes ago = Regenerated Dead Nerve cells in spinal due to precise 3D printed spinal scaffold... "Printing the scaffold lets researchers pattern guidance channels and place cells precisely—creating a “relay” that can bypass damaged tissue. Early-stage, but a credible path toward translational implants. Read: https://medicalxpress.com/news/2025-08-3d-scaffold-spinal-cord-injury.html " $BIB $JNJ
2 · Reply
SparkySC
SparkySC Jul. 2 at 3:44 AM
$SPY $QQQ $BIB $PFE $TLT WOW! A must read… https://www.vigilantfox.com/p/rfk-jr-unloads-disturbing-vaccine
1 · Reply
svertical1
svertical1 Jun. 23 at 11:31 PM
$BIB $CMPS $LXRX $VRTX Vertex had poor study design. Sciatica pain episode duration lasts on average 10 days. They asked for placebo effect at 12 weeks, ‘ how’s the pain now’. You have to look at the hourly/daily pain relief while patient would be experiencing pain, not some arbitrary ‘months’ later date.
0 · Reply
Latest News on BIB
BIB: A Tactical 2 X Leveraged Biotech ETF

Oct 23, 2025, 8:00 AM EDT - 2 days ago

BIB: A Tactical 2 X Leveraged Biotech ETF

Healthcare Sector Checkup As U.S. Looks To Change Regulations

May 30, 2025, 3:30 PM EDT - 5 months ago

Healthcare Sector Checkup As U.S. Looks To Change Regulations

AGNG ARKG BBC BBH BBP BIS BMED

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Feb 25, 2025, 11:06 AM EST - 8 months ago

Seeking Stocks With Vitality In The Volatile Healthcare Sector

IBB XLV AGNG ARKG BBC BBH BBP

Will The Next Batch Of Tech Earnings Encourage Investors To Rotate Back In?

Jul 30, 2024, 2:30 AM EDT - 1 year ago

Will The Next Batch Of Tech Earnings Encourage Investors To Rotate Back In?

AAPL AMZN ANSS BA FFIV GOOGL HSY

Equity CEFs/ETFs: Top Picks For 2024 - Part II

Jan 5, 2024, 11:01 AM EST - 1 year ago

Equity CEFs/ETFs: Top Picks For 2024 - Part II

AIO AIQ DIG EOI ETW EXG HQH

Why Now Could Be The Time To Consider Neuroscience Investments

Aug 27, 2022, 4:45 AM EDT - 3 years ago

Why Now Could Be The Time To Consider Neuroscience Investments

ARKG BBH FBT GNOM HELX IBB IBBQ

BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:48 PM
$BFS $BHC $BHR $BIB $BIGY 🔥
0 · Reply
Peachtreegal
Peachtreegal Oct. 17 at 3:35 PM
$ARTV $IBBQ $BIB
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 17 at 3:27 PM
Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally $ARTV $IBBQ $BIB https://stocktwits.com/news/equity/markets/artiva-biotherapeutics-gets-price-target-hike-from-wedbush/ch6sW9tR38A
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 16 at 3:22 PM
$FBIO + ( $DERM ) Older copper injections, sometimes prepared in-house, could be painful and, with long-term use, could cause kidney damage. In clinical trials for CUTX-101, adverse events were generally not considered related to the study treatment, highlighting its improved safety profile. Enhanced bioavailability and safety The specific formulation of CUTX-101 ensures better delivery of copper to the body and brain, where it is critically needed. CUTX-101 has been granted Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations. These designations recognize the drug's potential to provide significant clinical improvement over existing treatments for a rare condition with unmet medical needs. $DERM ( subsidiary of $FBIO OWNS ACCUTANE, see screenshots and link for how it helps treat male infertility . https://www.livescience.com/health/fertility-pregnancy-birth/acne-drug-accutane-may-restore-sperm-production-in-infertile-men-early-study-hints $BIB $JNJ
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 15 at 10:58 PM
$FBIO Updated link, more here: For more info on FIRST EVER TREATMENT for MENKES Disease, a Pediatric, often Fatal Condition, Pending Sept 30th PDUFA for $FBIO. And for latest Isotretinoin and Male Infertility Treatment studies, using Istotretinoin, AKA, ACCUTANE, which is owned by $DERM, a subsidiary of $FBIO, that can treat Male Infertility, based on recent studies. See link below and read quoted post below . https://x.com/ravagelaserbeak/status/1967719314229997659 Related tickers: $DERM $BIB $JNJ $MRK
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 15 at 8:31 PM
$FBIO + $DERM ($DERM is a subsidiary of $FBIO ) Aside from Sept 30th PDUFA = we have this = " For men with infertility caused by extremely low sperm counts or a complete lack of sperm, the only medical option is to undergo surgery to collect sperm directly from the testicles to then use for in vitro fertilization (IVF). But this is a significant surgery that involves discomfort; potential risks, such as infection; and a prolonged recovery period. Moreover, the surgery only yields sperm about half the time. Now, researchers are exploring an alternative: isotretinoin, better known as Accutane, a drug that has been used for decades to treat severe acne. In a small study published in July in the Journal of Assisted Reproduction and Genetics, the drug stimulated sperm production in some men who at baseline had no or very few sperm in their ejaculate. " Good Post on $FBIO More here = https://x.com/ravagelaserbeak/status/1967686200199889335?s=46 related tickers = $BIB $DERM $PFE $JNJ
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 3 at 4:58 PM
$GOOGL OH and we have our own Blockchain now to compete against $XRP lol.... and we're also $BIB on Pharma Treatment discovery by a Nobel Prize Laureate leading Google Deepmind, Demis Hassabis. Long. Price correcting up, now that Browser hurdle has been cleared, likely supports around 350+ in a few weeks. This is re-rate and has ZERO to do with Macro environments. The ONLY thing that had this down is eviscerated and completely gone.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 27 at 3:13 PM
$SSYS Im long $SSYS with Debbie Wasserman Schultz...Debbie Knows...things.... Stratasys posted this about 10 minutes ago = Regenerated Dead Nerve cells in spinal due to precise 3D printed spinal scaffold... "Printing the scaffold lets researchers pattern guidance channels and place cells precisely—creating a “relay” that can bypass damaged tissue. Early-stage, but a credible path toward translational implants. Read: https://medicalxpress.com/news/2025-08-3d-scaffold-spinal-cord-injury.html " $BIB $JNJ
2 · Reply
SparkySC
SparkySC Jul. 2 at 3:44 AM
$SPY $QQQ $BIB $PFE $TLT WOW! A must read… https://www.vigilantfox.com/p/rfk-jr-unloads-disturbing-vaccine
1 · Reply
svertical1
svertical1 Jun. 23 at 11:31 PM
$BIB $CMPS $LXRX $VRTX Vertex had poor study design. Sciatica pain episode duration lasts on average 10 days. They asked for placebo effect at 12 weeks, ‘ how’s the pain now’. You have to look at the hourly/daily pain relief while patient would be experiencing pain, not some arbitrary ‘months’ later date.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 23 at 9:50 PM
$CMPS Example: A $VRTX showed even WORSE BASELINE EFFECTS OF 2 at 12 weeks and even worse vs Placebo at 1.98. For their non opioid pain drug, results from phase 2 on December 19th 2024(last yr). THE STOCK PLUMMETS OVER 10%. Then Phase 3 results come, also don't impress much. A MONTH LATER FDA APPROVES THE SAME DRUG ON JANUARY 30th 2025. THE STOCK SKYROCKETS FOR DAYS, I RECALL THIS SPECIFICALLY BECUASE I AM IN A NON OPIOID DRUG STOCK $LXRX. LITERALLY ABOUT A MONTH LATER THE SAME 'DISAPPOINTING STREET EXPECTED RESULTS' WERE MEDICALLY SIGNIFICANT ENOUGH TO FDA GREENLIGHT IT. WE MISSED MAYBE BY A POINT AT 4 points vs 5 expected. (3.6) YOU HAVE TO BE MENTALLY UNSTABLE IF YOU THINK PRO PSYCLOCIBIN ROBERT KENNDY WILL NOT FIND THESE RESULTS MEDICALLY SIGNIFICANT FOR APPROVAL. $BIB
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 19 at 3:24 PM
$CMPS $BIB qhttps://www.livescience.com/health/mind/one-psychedelic-psilocybin-dose-eases-depression-for-years-study-reveals
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 17 at 3:04 PM
$CMPS = "Compass Pathways is expecting to release the top-line, 6-week (primary endpoint) results for their COMP005 Phase 3 trial (part of the larger COMP360 psilocybin treatment program for treatment-resistant depression) in late June 2025. " Single psilocybin trip delivers two years of depression relief for cancer patients Phase 2 trial reveals that a single dose of psilocybin offers long-term relief from symptoms of depression and anxiety. "Yes, RFK Jr. has expressed support for the therapeutic potential of psychedelics, including psilocybin, and has advocated for their use in mental health treatment. " "Criticism of FDA policies: He has criticized the FDA for its "aggressive suppression of psychedelics". " Now he runs this agency. https://www.sciencedaily.com/releases/2025/06/250616040215.htm $MRK $GILD $BIB
0 · Reply
jjon2121
jjon2121 May. 29 at 12:02 AM
$LABU $LABD $XBI $IBB $BIB Is this the reason for the AH turnaround? https://www.cnbc.com/2025/05/29/court-strikes-down-trump-reciprocal-tariffs.html
2 · Reply
macrossluvsrobotech
macrossluvsrobotech May. 15 at 1:06 PM
$LXRX $VTRS $NVO $BIB Two weeks ago. Edelman unofficially giving the new administration a second shot at considering T1D for Sota. Nice. Smells like Biden bias for last decision. Now under Dr Martin Makary at the helm and anti jabby JFK jr, looking good. https://www.linkedin.com/posts/taking-control-of-your-diabetes_update-from-dr-steve-edelman-this-morning-activity-7323060775802064897--mMx?utm_source=share&utm_medium=member_ios&rcm=ACoAAAsxtNMB_-3m9veO28z6qXYyCblWycfZlRA
2 · Reply
macrossluvsrobotech
macrossluvsrobotech May. 14 at 11:31 AM
$FET.X $BIB $GILD $NVDA YOUR PERSONAL MEDICAL / HEALTH AI AGENT WITH THE IMMUTABLE LEDGER TECHNOLOGY (BLOCKCHAIN) BAKED INTO IT, UNLIKE ANY OTHER AI TECH OUT THERE = TRULY DEMOCRATIC AND FREE FOR GOVT USE THE ONLY AND FIRST AI AGENT TECHH FOR WEB3
0 · Reply
SnoopDawg
SnoopDawg May. 12 at 12:50 AM
$BIB exec order will cause pharma to raise prices overseas to match domestic. More money for pharma.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech May. 9 at 10:55 PM
$GILD $BIB "HIV Drugs Linked to Lower Alzheimer’s Risk" whttps://neurosciencenews.com/nrtis-hiv-alzheimers-28859/
0 · Reply
jjon2121
jjon2121 Apr. 21 at 12:02 PM
$LABU $LABD $XBI $IBB $BIB Once again. Here is the biggest problem folks. Companies shying away from full buyouts. Most bullish Bio trend been pretty weak since Nov. https://www.bioworld.com/articles/719338-biopharma-m-and-as-plunge-in-q1-while-6686b-in-deals-beats-2024-average?v=preview
2 · Reply
macrossluvsrobotech
macrossluvsrobotech Apr. 20 at 12:48 AM
$LXRX + $NVO THEY MAKE A DEAL FOR LEXICONS ORAL WEIGHT LOSS PILL TO COMPETE WITH $LLY. BUY OUT?? Novo Nordisk and Lexicon Deal = "Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal By Sneha S K March 28, 20258:18 AM PDTUpdated 22 days ago" https://www.reuters.com/business/healthcare-pharmaceuticals/lexicon-license-obesity-drug-novo-nordisk-up-1-billion-deal-2025-03-28/ About LX9851 "LX9851 is an orally delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders. https://investors.lexpharma.com/news-releases/news-release-details/lexicon-present-preclinical-vivo-efficacy-data-demonstrating/" "Novo Nordisk Is Getting Absolutely Destroyed" https://futurism.com/neoscope/novo-nordisk-getting-destroyed "Novo Nordisk shares slump following Eli Lilly’s weight-loss pill success" https://finance.yahoo.com/news/novo-nordisk-shares-slump-following-140751424.html $HIMS $LLY $BIB
3 · Reply
macrossluvsrobotech
macrossluvsrobotech Apr. 15 at 4:47 PM
$BIB $HIMS $LLY $LXRX $NVO Just the messenger.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Apr. 15 at 11:58 AM
$LXRX + $NVO " Pfizer Halts Obesity-Drug Development. What It Means for Eli Lilly, Novo Nordisk." https://www.barrons.com/articles/pfizer-eli-lilly-novo-stock-price-obesity-drug-304c7c2f Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal By Sneha S K March 28, 20258:18 AM PDTUpdated 13 days ago https://www.reuters.com/business/healthcare-pharmaceuticals/lexicon-license-obesity-drug-novo-nordisk-up-1-billion-deal-2025-03-28/ $BIB $LLY $HIMS
0 · Reply